Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05651191
Other study ID # HRAIN01-ALL04-POC
Secondary ID
Status Recruiting
Phase Early Phase 1
First received
Last updated
Start date October 21, 2022
Est. completion date September 30, 2025

Study information

Verified date December 2022
Source Hrain Biotechnology Co., Ltd.
Contact Xuedong Sun, M.D.
Phone 0086-021-58552006
Email sunxuedong@dashengbio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a single-arm, open-label, dose-escalation trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of human CD19 targeted DASH CAR-T Cells injection, and to preliminarily observe the efficacy of the trial drug in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.


Description:

Subjects with relapsed/refractory B-cell acute lymphoblastic leukemia can participate if all eligibility criteria are met. Tests required to determine eligibility including disease assessments, a physical exam, Electrocardiograph, Computed tomography(CT)/Magnetic Resonance Imaging(MRI)/Positron Emission Tomography(PET), and blood draws. Subjects will receive preconditioning chemotherapy prior to the infusion of human CD19 targeted DASH CAR-T Cells injection. After the infusion, subjects will be followed for adverse events, pharmacokinetic/pharmacodynamics characteristics, efficacy of human CD19 targeted DASH CAR-T cells. Study procedures may be performed while hospitalized.


Recruitment information / eligibility

Status Recruiting
Enrollment 9
Est. completion date September 30, 2025
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:Subjects must meet all of the following criteria to be enrolled: - 18 to 70 years old (including cut-off value), Male and female; - Expected survival > 12 weeks; - ECOG score 0-1; - Bone marrow examination clearly diagnosed as B-cell acute lymphoblastic leukemia, CD19 positive, and who met one of the following conditions: 1. Those who failed to achieve CR after at least 2 courses of standard chemotherapy or had early relapse after complete remission (<12 months) or late relapse after complete remission (= 12 months) and failed to achieve CR after 1 course of standard chemotherapy; 2. For Ph+ ALL: in addition to receiving at least 2 courses of standard chemotherapy, at least two TKIs should be treated with no complete remission or relapse after complete remission; (Patients who cannot tolerate TKI therapy or have TKI treatment contraindications or have T315i mutation are excluded); 3. Those who relapse after stem cell transplantation are not affected by previous treatments; - The venous access required for collection can be established and leukapheresis can be carried according to the judgement of investigators; - Liver, kidney and cardiopulmonary functions meet the following requirements: 1. Serum creatinine = 1.5×ULN; 2. Left ventricular ejection fraction > 50%; 3. Baseline oxygen saturation > 96%; 4. Total bilirubin = 2×ULN; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3×ULN (As judged by the investigator, the elevation of transaminase caused by the ALL disease itself, ALT and AST = 5×ULN); - Able to understand and sign the Informed Consent Document. Exclusion Criteria:Any one of the following conditions cannot be selected as a subject: - Graft-versus-host disease (GVHD), or need to use immunosuppressants after transplantation; - Patients with hyperleukocytosis (white blood cell count = 50×10^9/L) or whose disease progressed rapidly according to the investigator's judgment at the time of enrollment and cannot ensure the completion of a complete treatment cycle; - Malignant tumors other than acute lymphoblastic leukemia within 5 years prior to screening, in addition to adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical resection, ductal carcinoma in situ after radical resection and thyroid cancer after radical resection; - Subjects with positive Hepatitis B surface antigen (HBsAg) or Hepatitis B core antibody (HBcAb) and peripheral blood hepatitis B virus (HBV) DNA titer detection higher than the lower limit of the research center can detect; hepatitis C virus (HCV) antibody positive and peripheral blood HCV RNA positive; human immunodeficiency virus (HIV) antibody positive; syphilis detection positive; - Any instability of systemic disease, including but not limited to unstable angina, cerebrovascular accident, or transient cerebral ischemic (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), congestive heart failure (New York heart association (NYHA) classification = III), need drug therapy of severe arrhythmia, liver, kidney, or metabolic disease; - Active or uncontrollable infection requiring systemic therapy within 14 days prior to enrollment; - Pregnant or lactating woman, and female subject who plans to have a pregnancy within 1 year after cell transfusion, or male subject whose partner plans to have a pregnancy within 1 year after cell transfusion; - Received CAR-T treatment or other gene therapies before enrollment; - Patients with symptoms of central nervous system; - Subjects who are receiving systemic steroid treatment and requiring long-term systemic steroid treatment during the treatment as determined by the investigator before screening (except inhalation or topical use); - The investigators consider other conditions unsuitable for enrollment.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Human CD19 Targeted DASH CAR-T Cells Injection
Autologous genetically modified anti-CD19 CAR transduced T cells

Locations

Country Name City State
China The Second Affiliated Hospital of Nanchang University Nanchang Jiangxi

Sponsors (2)

Lead Sponsor Collaborator
Hrain Biotechnology Co., Ltd. Second Affiliated Hospital of Nanchang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose limited toxicity (DLT) Safety Indicators 28 days post infusion
Secondary Pharmacokinetics parameters - the highest concentration of Human CD19 Targeted DASH CAR-T Cells amplified in peripheral blood after reinfusion Effectiveness Metrics 2 years post infusion
Secondary Pharmacokinetics parameters - the time to reach the highest concentration of Human CD19 Targeted DASH CAR-T Cells amplified in peripheral blood after reinfusion Effectiveness Metrics 2 years post infusion
Secondary Pharmacokinetics parameters - the 28-day area under the curve of Human CD19 Targeted DASH CAR-T Cells amplified in peripheral blood after reinfusion Effectiveness Metrics 2 years post infusion
Secondary Pharmacodynamics characteristics - the detection values of IL-6, IFN-?, IL-15 cytokines in peripheral blood Effectiveness Metrics 2 years post infusion
Secondary Overall response rate (ORR, include CR and CRi) after administration Effectiveness Metrics 3 months post infusion
Secondary Duration of remission (DOR) after administration Effectiveness Metrics 2 years post infusion
Secondary Overall Survival (OS) after administration Effectiveness Metrics 2 years post infusion
See also
  Status Clinical Trial Phase
Recruiting NCT03671460 - CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. Phase 1
Recruiting NCT06056752 - QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Phase 1
Recruiting NCT05016947 - Venetoclax Plus Inotuzumab for B-ALL Phase 1
Suspended NCT01974479 - Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia Phase 1
Completed NCT00289562 - Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia Phase 1/Phase 2
Recruiting NCT06034275 - Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies Phase 1
Recruiting NCT04191941 - Treatment of Hematological Malignancy With Novel CAR-T Cells. Early Phase 1
Recruiting NCT05333302 - Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma Phase 1
Recruiting NCT04129099 - A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL Early Phase 1
Recruiting NCT04150497 - Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) Phase 1
Withdrawn NCT05571540 - Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL Phase 1/Phase 2
Recruiting NCT03281551 - Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma Phase 1
Recruiting NCT05379647 - Natural Killer (NK) Cell Therapy for B-Cell Malignancies Phase 1
Withdrawn NCT04156659 - Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL Phase 2
Recruiting NCT04094311 - Study of Out of Specification for Tisagenlecleucel Phase 3
Completed NCT01207388 - Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) Phase 2
Active, not recruiting NCT03467256 - CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL Phase 1/Phase 2
Terminated NCT04844086 - RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies Phase 1
Recruiting NCT05648019 - CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol Phase 2
Not yet recruiting NCT04595162 - A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL Phase 1